Skip to main content

Table 1 Baseline patient characteristics

From: Injection of hydrogel spacer increased maximal intrafractional prostate motion in anterior and superior directions during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer

Parameter

Non-spacer group

Spacer group

P value

N = 30

N = 8

 

Age, years, median (range)

73 (58–85)

79 (66–84)

0.22b

Body mass index, mean ± SD

23.5 ± 2.7

23.6 ± 3.4

0.93b

Clinical T stage, n (%)

  

0.78c

 1c

6 (20%)

3 (37.5%)

 

 2a

13 (43.3%)

2 (25.0%)

 

 2b

2 (6.7%)

1 (12.5%)

 

 2c

5 (16.7%)

2 (25.0%)

 

 3a

1 (3.3%)

0 (0%)

 

 3b

2 (6.7%)

0 (0%)

 

 4

1 (3.3%)

0 (0%)

 

Mean monitoring time, seconds, mean ± SD

275 ± 42

279 ± 33

0.82b

Neoadjuvant ADT, n (%)

  

0.99c

 No

9 (30.0%)

2 (25.0%)

 

 Yes

21 (70.0%)

6 (75.0%)

 

History of abdominal surgery, n (%)

  

0.65c

 No

21 (70.0%)

7 (87.5%)

 

 Yes

9 (30.0%)

1 (12.5%)

 

Prostate volume*, cc, mean ± SD

31.1 ± 12.4

25.0 ± 9.2

0.22b

Rectum volume*a, cc, mean ± SD

55.4 ± 15.5

43.4 ± 9.0

0.047b†

Bladder volume*, cc, mean ± SD

277.1 ± 169.2

205.1 ± 77.9

0.26b

  1. Abbreviations: ADT androgen deprivation therapy, SD standard deviation
  2. *Measured on planning CT
  3. aFrom the slice 1 cm above the PTV to the slice 1 cm below the PTV in axial slices
  4. bBy unpaired t-test
  5. cBy χ2-test
  6. †Statistically significant